Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PRCT Procept BioRobotics Corp
- Stocks
- Healthcare
- NASDAQ: PRCT
Price (delayed)
$56.57
Market cap
$3.13B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.69
Enterprise value
$2.9B
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic
Highlights
PRCT's gross profit has surged by 87% year-on-year and by 14% since the previous quarter
Procept BioRobotics's revenue has surged by 59% YoY and by 11% QoQ
The equity is up by 47% year-on-year but it has declined by 3.2% since the previous quarter
The quick ratio is up by 4.3% year-on-year but it has declined by 3.2% since the previous quarter
Key stats
What are the main financial stats of PRCT
Market
Valuations
Earnings
Shares outstanding
55.33M
Market cap
$3.13B
Enterprise value
$2.9B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.97
Price to sales (P/S)
12.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.62
Revenue
$249.12M
Gross profit
$156.23M
Operating income
-$96.4M
Net income
-$90.19M
EBIT
-$86.18M
EBITDA
-$81.07M
Free cash flow
-$88.21M
Per share
Balance sheet
Liquidity
EPS
-$1.69
EPS diluted
-$1.69
Free cash flow per share
-$1.61
Book value per share
$7.1
Revenue per share
$4.54
TBVPS
$9.44
Total assets
$519.38M
Total liabilities
$130.22M
Debt
$81.81M
Equity
$389.16M
Working capital
$413.73M
Debt to equity
0.21
Current ratio
8.95
Quick ratio
7.6
Net debt/EBITDA
2.89
Margins
Efficiency
Dividend
EBITDA margin
-32.5%
Gross margin
62.7%
Net margin
-36.2%
Operating margin
-38.7%
Return on assets
-20%
Return on equity
-28.1%
Return on invested capital
-40%
Return on capital employed
-18.4%
Return on sales
-34.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRCT stock price
How has the Procept BioRobotics stock price performed over time
Intraday
-1.79%
1 week
-4%
1 month
-2.47%
1 year
-8.57%
YTD
-29.74%
QTD
-1.79%
Financial performance
How have Procept BioRobotics's revenue and profit performed over time
Revenue
$249.12M
Gross profit
$156.23M
Operating income
-$96.4M
Net income
-$90.19M
Gross margin
62.7%
Net margin
-36.2%
PRCT's gross profit has surged by 87% year-on-year and by 14% since the previous quarter
Procept BioRobotics's revenue has surged by 59% YoY and by 11% QoQ
The net margin is up by 45% year-on-year and by 11% since the previous quarter
The company's operating margin rose by 44% YoY and by 10% QoQ
Price vs fundamentals
How does PRCT's price correlate with its fundamentals
Growth
What is Procept BioRobotics's growth rate over time
Valuation
What is Procept BioRobotics stock price valuation
P/E
N/A
P/B
7.97
P/S
12.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.62
Procept BioRobotics's EPS has increased by 20% YoY and by 3.4% QoQ
The equity is up by 47% year-on-year but it has declined by 3.2% since the previous quarter
PRCT's P/B is 34% below its last 4 quarters average of 12.1
Procept BioRobotics's revenue has surged by 59% YoY and by 11% QoQ
The stock's price to sales (P/S) is 29% less than its last 4 quarters average of 17.6
Efficiency
How efficient is Procept BioRobotics business performance
Procept BioRobotics's return on sales has increased by 46% YoY and by 11% QoQ
The ROE has grown by 32% YoY and by 11% from the previous quarter
PRCT's ROIC is up by 29% YoY and by 5% QoQ
Procept BioRobotics's ROA has increased by 28% YoY and by 9% from the previous quarter
Dividends
What is PRCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRCT.
Financial health
How did Procept BioRobotics financials performed over time
Procept BioRobotics's total assets has increased by 36% YoY but it has decreased by 2.7% from the previous quarter
The company's total liabilities rose by 10% YoY
The debt is 79% smaller than the equity
The equity is up by 47% year-on-year but it has declined by 3.2% since the previous quarter
The debt to equity has declined by 32% year-on-year but it has increased by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.